Amneal Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US03168L1052

SecurityAMRX / Amneal Pharmaceuticals, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership4,637,185 shares
Latest Disclosed Value $ 57,640,225
Morgan Stanley reports 3.75% decrease in ownership of AMRX / Amneal Pharmaceuticals, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 4,637,185 shares of Amneal Pharmaceuticals, Inc. (US:AMRX) valued at $57,640,210 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 4,818,099 shares of Amneal Pharmaceuticals, Inc.. This represents a change in shares of -3.75% during the quarter. The current value of the position is $63,761,294 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 4,637,185 -180,914 -3.75 57,640 -5.05 0.0035
2026-05-27 2025-12-31 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 4,818,099 1,315,018 37.54 60,708 73.13 0.0036
2026-02-13 2025-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 4,818,099 1,315,018 60,708 0.0036
2026-05-27 2025-09-30 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 3,503,081 1,005,848 40.28 35,066 73.57 0.0021
2025-11-14 2025-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 3,503,081 1,005,848 35,066 0.0021
2025-08-15 2025-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 2,497,233 876,232 54.05 20,203 48.73 0.0013
2025-05-15 2025-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 1,621,001 133,240 8.96 13,584 15.28 0.0010
2025-05-15 2024-12-31 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 1,487,761 242,585 19.48 11,783 13.75 0.0008
2025-02-14 2024-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 1,487,761 242,585 11,783 0.0008
2025-05-14 2024-09-30 13F/A-2 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 1,245,176 209,571 20.24 10,360 57.53 0.0008
2025-02-14 2024-09-30 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 1,245,176 209,571 10,360 0.0008
2024-11-14 2024-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 1,245,176 209,571 10,360 0.0001
2025-05-14 2024-06-30 13F/A-2 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 1,035,605 79,643 8.33 6,576 13.52 0.0005
2024-10-17 2024-06-30 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 1,035,605 79,643 6,576 0.0005
2024-08-14 2024-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 1,035,605 79,643 6,576 0.0005
2024-10-17 2024-03-31 13F/A-2 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 955,962 513,669 116.14 5,793 115.83 0.0005
2024-08-16 2024-03-31 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 955,962 513,669 5,793 0.0001
2024-05-15 2024-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 955,962 513,669 5,793 0.0005
2024-08-16 2023-12-31 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 442,293 66,117 17.58 2,685 69.12 0.0002
2024-02-13 2023-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 442,293 66,117 2,685 0.0002
2023-11-15 2023-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 376,176 -59,349 -13.63 1,587 17.56 0.0002
2023-08-14 2023-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 435,525 53,037 13.87 1,350 154.24 0.0001
2023-05-15 2023-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 382,488 -3,838,510 -90.94 532 -93.68 0.0001
2023-02-14 2022-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 4,220,998 3,813,489 935.80 8,400 920.53 0.0010
2022-11-14 2022-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 407,509 -54,911 -11.87 823 -44.01 0.0001
2022-10-27 2022-06-30 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 462,420 39,691 9.39 1,470 -16.57 0.0002
2022-08-15 2022-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 462,420 39,691 1,470 0.0000
2022-10-27 2022-03-31 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 422,729 8,649 2.09 1,762 -11.19 0.0002
2022-05-13 2022-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 422,729 8,649 1,762 0.0002
2022-02-14 2021-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 414,080 99,697 31.71 1,984 18.17 0.0002
2021-11-15 2021-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 314,383 147,054 87.88 1,679 96.14 0.0002
2021-08-23 2021-06-30 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 167,329 13,005 8.43 856 -17.45 0.0001
2021-08-16 2021-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 167,329 13,005 856 0.0000
2021-05-17 2021-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 154,324 -89,736 -36.77 1,037 -7.08 0.0002
2021-02-16 2020-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 244,060 -6,978 -2.78 1,116 14.58 0.0002
2020-11-13 2020-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 251,038 163,848 187.92 974 134.70 0.0002
2020-08-14 2020-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 87,190 -8,905 -9.27 415 24.25 0.0001
2020-05-26 2020-03-31 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 96,095 -217,288 -69.34 334 -77.90 0.0001
2020-05-15 2020-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 96,095 -217,288 334 25.6582
2020-02-14 2019-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 313,383 -1,717,078 -84.57 1,511 -74.34 0.0004
2019-11-14 2019-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 2,030,461 1,994,724 5,581.68 5,889 2,200.39 0.0016
2019-08-14 2019-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 35,737 7,390 26.07 256 -36.32 0.0001
2019-05-15 2019-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 28,347 -115,791 -80.33 402 -79.38 0.0001
2019-02-14 2018-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 144,138 -133,934 -48.17 1,950 -68.40 0.0006
2019-04-23 2018-09-30 13F/A-2 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 278,072 -40,128 -12.61 6,171 18.17 0.0015
2018-11-20 2018-09-30 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 278,072 0 6,171 0.0015
2018-11-14 2018-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 278,072 6,171
2019-04-23 2018-06-30 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 318,200 318,200 5,222 0.0014
2018-08-14 2018-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 318,200 5,222 0.0014
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.